modelR01AD59
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | MometasoneCombinations | |
| ATC code: | R01AD59 | route: | intranasal |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 300 | L |
| clearance: | 40 | L/h |
| other parameters in model implementation | ||
Mometasone is a potent synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It is commonly used in combination with other agents for nasal administration to treat symptoms of allergic rhinitis and nasal polyps. Mometasone is approved and widely used in many countries in nasal spray formulations, often combined with other agents such as azelastine.
Pharmacokinetics
Estimated pharmacokinetic parameters for typical adult healthy individuals after nasal administration, as no direct published PK data on mometasone combination nasal sprays (R01AD59) are available. Estimates are based on known PK characteristics for nasal mometasone furoate.
References
Wolthers, OD (2013). New patents of fixed combinations of nasal antihistamines and corticosteroids in allergic rhinitis. Recent patents on inflammation & allergy drug discovery 7(3) 223–228. DOI:10.2174/1872213x113079990019 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23862774
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)